Vaxgen: more good news

The company furthest along in releasing an AIDS vaccine has released more good news: the HIV/AIDS vaccine, AIDSVAX B/B, induces antibodies to the five most common HIV subtypes according to an article published today in the journal Vaccine. “Once again we see evidence that AIDSVAX induces a more robust immune response than we originally anticipated,” said Donald P. Francis, M.D., D.Sc., president and co-founder of VaxGen. The stock is up 30 cents on the report. Now if they could just get some analyst coverage to bring in the insitutional investors.